Related Experiment Video
Updated: Oct 13, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
ACTH for epileptic spasms in Leigh syndrome with SLC19A3 mutation can induce status dystonicus
Hiroki Hoshino1, Hideaki Kanemura1
1Department of Pediatrics, Toho University, Sakura Medical Center, 564-1, Shimoshizu, Sakura, Chiba 285-0841, Japan.
Abstract:
Patients with Leigh syndrome (LS) sometimes develop epileptic spasms (ES). ACTH treatment for ES may be effective without serious adverse events in some patients with LS. Status dystonicus is a life-threatening disorder characterized by an acute exacerbation of generalized dystonia and often develops as a triggered event. The underlying pathophysiology of status dystonicus remains unclear. To our knowledge, there has been no reported case of status dystonicus associated with ACTH treatment. Here, we describe the first reported patient with LS, harbouring compound heterozygous mutations in SLC19A3 gene, who developed status dystonicus following initial intramuscular injection of a course of ACTH treatment for ES. Stressors can precipitate acute exacerbation in SLC19A3-related disorders. Interestingly, in this patient, external discomfort stimuli tended to induce transient hypertonia with opisthotonos. This report suggests that attention should be paid to acute exacerbation of generalized dystonia when ACTH treatment for ES is started in patients with LS, who have dystonia tend to exacerbate transiently by external discomfort stimuli.
More Related Videos
07:20Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
09:39Direct-current Stimulation and Multi-electrode Array Recording of Seizure-like Activity in Mice Brain Slice Preparation
Published on: June 7, 2016
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Spasmolytic Agents: Chemical Classification
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
ATP Synthase: Structure
Skeletal Muscle Relaxants: Adverse Effects
Unlike...